Literature DB >> 8148375

Characterisation of functional domains within the mouse erythropoietin 3' enhancer conveying oxygen-regulated responses in different cell lines.

C W Pugh1, B L Ebert, O Ebrahim, P J Ratcliffe.   

Abstract

We have analysed sequences within the mouse erythropoietin enhancer which are required for oxygen regulated operation in the erythropoietin producing cell line, HepG2, and in two non-erythropoietin producing cell lines; the lung fibroblastoid cell line a23, and mouse erythroleukaemia (MEL) cells. At least three critical sites were demonstrated within a 96 nucleotide sequence. Oxygen regulated operation was dependent on sites within the first 26 nucleotides. Sequences lying 3' to this region modulated enhancer function but did not themselves convey oxygen regulated operation. In HepG2 cells these 3' sequences co-operated to permit operation of the inducible element at a distance from a promoter, but in MEL cells 3' sequences repressed activity of the inducible element. Though operation of this 3' sequence differed according to the cell type, oxygen regulated operation was dependent on the same two critical sites in the 5' region in both erythropoietin producing and non-erythropoietin producing cells. These findings support the existence of a widespread oxygen sensing system in mammalian cells which is similar to that operating in specific cells to regulate erythropoietin production, and they indicate that the system activates factors with similar DNA sequence specificity in different cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8148375     DOI: 10.1016/0167-4781(94)90289-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  William Kaelin, Peter Ratcliffe, and Gregg Semenza receive the 2016 Albert Lasker Basic Medical Research Award.

Authors:  Jillian H Hurst
Journal:  J Clin Invest       Date:  2016-09-13       Impact factor: 14.808

2.  High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq.

Authors:  Johannes Schödel; Spyros Oikonomopoulos; Jiannis Ragoussis; Christopher W Pugh; Peter J Ratcliffe; David R Mole
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

Review 3.  The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy.

Authors:  Najah Albadari; Shanshan Deng; Wei Li
Journal:  Expert Opin Drug Discov       Date:  2019-05-09       Impact factor: 6.098

Review 4.  Erythropoietin.

Authors:  H Franklin Bunn
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

5.  Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer.

Authors:  J D Firth; B L Ebert; C W Pugh; P J Ratcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

6.  Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein.

Authors:  B L Ebert; H F Bunn
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

Review 7.  The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy.

Authors:  G U Dachs; I J Stratford
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 8.  Erythropoietin: a model system for studying oxygen-dependent gene regulation.

Authors:  H F Bunn; J Gu; L E Huang; J W Park; H Zhu
Journal:  J Exp Biol       Date:  1998-04       Impact factor: 3.312

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.